WO2005092882A1 - Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires - Google Patents

Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires Download PDF

Info

Publication number
WO2005092882A1
WO2005092882A1 PCT/IB2005/000389 IB2005000389W WO2005092882A1 WO 2005092882 A1 WO2005092882 A1 WO 2005092882A1 IB 2005000389 W IB2005000389 W IB 2005000389W WO 2005092882 A1 WO2005092882 A1 WO 2005092882A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
methyl
reaction
compound
Prior art date
Application number
PCT/IB2005/000389
Other languages
English (en)
Inventor
Chikara Uchida
Kiyoshi Kawamura
Original Assignee
Pfizer Japan, Inc.
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Japan, Inc., Pfizer Inc. filed Critical Pfizer Japan, Inc.
Publication of WO2005092882A1 publication Critical patent/WO2005092882A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Cette invention porte sur un composé de formula (I): dans laquelle Rl représente un atome d'halogène; R2 représente un atome d'hydrogène etc.; R3 représente un groupe alkyle possédant de 1 à 4 atomes de carbone, etc.;R4 représente un atome d'hydrogène, un groupe hydroxy, un groupe carboxy, etc.; A représente un atome d'oxygène, etc. L'invention porte également sur des sels acceptables d'un point de vue pharmaceutique de ces composés. Ces composés ont une activité agonistique du récepteur 5-HT4 et sont donc utiles dans le traitement du reflux gastro-oesophagien, de la dyspepsie non ulcéreuse, de la dyspepsie fonctionnelle, du syndrome du côlon irritable ou autre chez un mammifère tel qu'un être humain.
PCT/IB2005/000389 2004-03-01 2005-02-16 Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires WO2005092882A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54941504P 2004-03-01 2004-03-01
US60/549,415 2004-03-01

Publications (1)

Publication Number Publication Date
WO2005092882A1 true WO2005092882A1 (fr) 2005-10-06

Family

ID=34960499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/000389 WO2005092882A1 (fr) 2004-03-01 2005-02-16 Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires

Country Status (1)

Country Link
WO (1) WO2005092882A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007048643A1 (fr) * 2005-10-28 2007-05-03 Glaxo Group Limited Nouveau composé
WO2007068739A1 (fr) * 2005-12-16 2007-06-21 Glaxo Group Limited Nouveaux composes
WO2007096352A1 (fr) * 2006-02-22 2007-08-30 Glaxo Group Limited 5-amino-6-bromo-n-{[1-(tétrahydro-2h-pyrann-4-ylméthyl)-4-pipéridinyl] méthyl}-3,4 -dihydro-2h-chromène-8-carboxamide en tant qu'agoniste du récepteur 5-ht4
US7375114B2 (en) 2004-04-07 2008-05-20 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7396933B2 (en) 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
US7399862B2 (en) 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
US7419989B2 (en) 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
US7446114B2 (en) 2005-03-02 2008-11-04 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
WO2011099305A1 (fr) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2014147636A1 (fr) * 2013-03-20 2014-09-25 Suven Life Sciences Limited Dérivés 5-amino-quinoline-8-carboxamides en tant qu'agonistes du récepteur 5-ht4
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
WO2016128990A1 (fr) * 2015-02-13 2016-08-18 Suven Life Sciences Limited Composés d'amide en tant qu'agonistes du récepteur de 5-ht4
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
US11427540B2 (en) 2019-07-11 2022-08-30 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033186A1 (fr) * 1995-04-18 1996-10-24 Pharmacia & Upjohn S.P.A. Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht¿4?
WO1997031897A1 (fr) * 1996-02-29 1997-09-04 Janssen Pharmaceutica N.V. Nouvelles 4-((4'-aminobenzoyl)-oxymethyl)-piperidines n-substituees ayant des proprietes gastrocinetiques
WO1999002494A1 (fr) * 1997-07-11 1999-01-21 Janssen Pharmaceutica N.V. Benzamides monocycliques gastrocinetiques de derives 4-(aminomethyl)-piperidine
EP1076055A1 (fr) * 1998-04-28 2001-02-14 Dainippon Pharmaceutical Co., Ltd. Derives de 1- (1-substituee-4-piperidinyle)methyle]-4-piperidine, procede de production de ceux-ci, compositions medicinales contenant ces composes et intermediaires de ces composes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033186A1 (fr) * 1995-04-18 1996-10-24 Pharmacia & Upjohn S.P.A. Derives de dihydrobenzofurane substitues utilises en tant qu'agonistes de 5-ht¿4?
WO1997031897A1 (fr) * 1996-02-29 1997-09-04 Janssen Pharmaceutica N.V. Nouvelles 4-((4'-aminobenzoyl)-oxymethyl)-piperidines n-substituees ayant des proprietes gastrocinetiques
WO1999002494A1 (fr) * 1997-07-11 1999-01-21 Janssen Pharmaceutica N.V. Benzamides monocycliques gastrocinetiques de derives 4-(aminomethyl)-piperidine
WO1999002156A1 (fr) * 1997-07-11 1999-01-21 Janssen Pharmaceutica N.V. Benzamides bicycliques gastrocinetiques de derives 4-(aminomethyle)-piperidine substitues en 3 ou en 4
EP1076055A1 (fr) * 1998-04-28 2001-02-14 Dainippon Pharmaceutical Co., Ltd. Derives de 1- (1-substituee-4-piperidinyle)methyle]-4-piperidine, procede de production de ceux-ci, compositions medicinales contenant ces composes et intermediaires de ces composes

Cited By (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9873692B2 (en) 2004-04-07 2018-01-23 Theravance Biopharma R&D Ip, Llc Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8962653B2 (en) 2004-04-07 2015-02-24 Theravance Biopharma R&D Ip, Llc Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US9353106B2 (en) 2004-04-07 2016-05-31 Theravance Biopharma R&D Ip, Llc Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7375114B2 (en) 2004-04-07 2008-05-20 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US9630960B2 (en) 2004-04-07 2017-04-25 Theravance Biopharma R&D Ip, Llc Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7763637B2 (en) 2004-04-07 2010-07-27 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4, receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7534889B2 (en) 2004-11-05 2009-05-19 Theravance, Inc. 5-HT4 receptor agonist compounds
US7498442B2 (en) 2004-11-05 2009-03-03 Theravance, Inc. Quinolinone-carboxamide compounds
US7399862B2 (en) 2004-11-05 2008-07-15 Theravance, Inc. 5-HT4 receptor agonist compounds
US7396933B2 (en) 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
US7419989B2 (en) 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
US7786136B2 (en) 2004-12-22 2010-08-31 Theravance, Inc. Indazole-carboxamide compounds
US8003664B2 (en) 2004-12-22 2011-08-23 Theravance, Inc. Indazole-carboxamide compounds
US7875629B2 (en) 2005-03-02 2011-01-25 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
US7446114B2 (en) 2005-03-02 2008-11-04 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
WO2007048643A1 (fr) * 2005-10-28 2007-05-03 Glaxo Group Limited Nouveau composé
EP2305652A2 (fr) 2005-12-08 2011-04-06 Novartis AG Dérivés de quinazolinone trisubstituée en tant qu'agonistes de vanilloïde
WO2007068739A1 (fr) * 2005-12-16 2007-06-21 Glaxo Group Limited Nouveaux composes
WO2007096352A1 (fr) * 2006-02-22 2007-08-30 Glaxo Group Limited 5-amino-6-bromo-n-{[1-(tétrahydro-2h-pyrann-4-ylméthyl)-4-pipéridinyl] méthyl}-3,4 -dihydro-2h-chromène-8-carboxamide en tant qu'agoniste du récepteur 5-ht4
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US8569344B2 (en) 2008-06-02 2013-10-29 Zalicus Pharmaceuticals Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US9096522B2 (en) 2008-06-02 2015-08-04 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US9593102B2 (en) 2008-10-14 2017-03-14 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US10144709B2 (en) 2008-10-14 2018-12-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US9676718B2 (en) 2008-10-14 2017-06-13 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010084050A2 (fr) 2009-01-13 2010-07-29 Novartis Ag Dérivés de quinazolinone utiles comme antagonistes vanilloïdes
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US9663455B2 (en) 2009-11-06 2017-05-30 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US11524935B2 (en) 2009-11-06 2022-12-13 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US10202335B2 (en) 2009-11-06 2019-02-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9688620B2 (en) 2009-11-06 2017-06-27 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
WO2011092290A1 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de pyrazolo[5,1-b] utilisés en tant qu'antagonistes du récepteur de crf-1
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
WO2011095450A1 (fr) 2010-02-02 2011-08-11 Novartis Ag Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
JP2013519630A (ja) * 2010-02-12 2013-05-30 ラクオリア創薬株式会社 認知症治療のための５−ｈｔ４受容体アゴニスト
WO2011099305A1 (fr) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. Agonistes du récepteur 5-ht4 pour le traitement de la démence
US8980922B2 (en) 2010-02-12 2015-03-17 Raqualia Pharma Inc. 5-HT4 receptor agonists for the treatment of dementia
RU2569733C2 (ru) * 2010-02-12 2015-11-27 Раквалиа Фарма Инк. Агонисты 5-нт4-рецепторов для лечения деменции
CN102753172A (zh) * 2010-02-12 2012-10-24 拉夸里亚创药株式会社 用于治疗痴呆的5-ht4受体激动剂
US9907777B2 (en) 2010-06-30 2018-03-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
WO2012164473A1 (fr) 2011-05-27 2012-12-06 Novartis Ag Dérivés de pipéridine 3-spirocyclique comme agonistes du récepteur de la ghréline
WO2013164790A1 (fr) 2012-05-03 2013-11-07 Novartis Ag Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
WO2014147636A1 (fr) * 2013-03-20 2014-09-25 Suven Life Sciences Limited Dérivés 5-amino-quinoline-8-carboxamides en tant qu'agonistes du récepteur 5-ht4
US9790211B2 (en) 2013-03-20 2017-10-17 Suven Life Sciences Limited 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
EA029365B1 (ru) * 2013-03-20 2018-03-30 Сувен Лайф Сайенсиз Лимитед 5-амино-хинолин-8-карбоксамидные производные в качестве агонистов 5-htрецептора
JP2016516089A (ja) * 2013-03-20 2016-06-02 スヴェン・ライフ・サイエンシズ・リミテッド ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体
AU2016217461B2 (en) * 2015-02-13 2018-07-05 Suven Life Sciences Limited Amide compounds as 5-HT4 receptor agonists
US9957257B2 (en) 2015-02-13 2018-05-01 Suven Life Sciences Limited Amide compounds as 5-HT4 receptor agonists
WO2016128990A1 (fr) * 2015-02-13 2016-08-18 Suven Life Sciences Limited Composés d'amide en tant qu'agonistes du récepteur de 5-ht4
EA034618B1 (ru) * 2015-02-13 2020-02-27 Сувен Лайф Сайенсиз Лимитед Амидные соединения в качестве агонистов рецептора 5-ht
CN107406434B (zh) * 2015-02-13 2020-09-11 苏文生命科学有限公司 作为5-ht4受体激动剂的酰胺化合物
CN107406434A (zh) * 2015-02-13 2017-11-28 苏文生命科学有限公司 作为5‑ht4受体激动剂的酰胺化合物
US11427540B2 (en) 2019-07-11 2022-08-30 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
US11649207B2 (en) 2019-07-11 2023-05-16 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof

Similar Documents

Publication Publication Date Title
WO2005092882A1 (fr) Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires
EP1713797B1 (fr) Derives de 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide presentant une activite agoniste du recepteur 5-ht4
EP0930298B1 (fr) Derives de piperidine fluores a disubstitution en position 1,4
KR100883236B1 (ko) 케모카인 수용체 길항제
EP2212282B1 (fr) Carboxamides de n-phényl-bipyrrolidine substitués et leur utilisation thérapeutique
NZ550006A (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of FAAH enzyme inhibitors
AU2010247212B2 (en) 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
JP6746613B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
CA2545092C (fr) Composes d'acide quinolonecarboxylique a activite agoniste du recepteur 5-ht4
JP2012526784A (ja) ７−アザ−スピロ［３．５］ノナン−７−カルボン酸エステル誘導体、これらの調製およびこれらの治療用途
EP1910340A1 (fr) Derives d ndazolecarboxamides en tant qu'agonistes des recepteurs 5ht4
PL193484B1 (pl) Etery piperydynyloaminometylo-trifluorometylocykliczne, związki pośrednie, środek farmaceutyczny i zastosowanie eterów piperydynyloaminometylo-trifluorometylocyklicznych
EP4013751A1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CA2908805A1 (fr) Derive de morphinane
EP2364295B1 (fr) Dérivés de 3-(benzylamino)pyrrolidine et leur utilisation comme antagonistes du récepteur nk-3
KR20150068960A (ko) 치환된 카바메이트 화합물 및 일시적 수용체 전위(trp) 채널 길항제로서의 이의 용도
WO2006117754A1 (fr) Derives d'azabicyclo [3.1.0] hexane 3,6-disubstitues utilises comme antagonistes du recepteur muscarinique
WO2021028323A1 (fr) Dérivés de (2-acétamidyle)thio-bêta-d-galactopyranoside
CA2380074C (fr) Nouveaux derives amide
CA2614000A1 (fr) Nouveaux derives 1h-indole-pyridinecarboxamides et 1h-indole-piperidinecarboxamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA06007348A (en) 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4
EP2200982A1 (fr) Dérivés de pipéridine en tant qu'antagonistes du récepteur nk3
WO2023249872A1 (fr) Composés bicycliques fusionnés substitués et procédés de traitement associés
NO860007L (no) Fremgangsmaate til fremstilling av nye trisubstituerte azacykloalkaner, resp. azacykloalkener.
JP2006327947A (ja) ４−（２−オキソ−２，３−ジヒドロ−１ｈ−ベンズイミダゾール−１−イル）ピペリジン−３−カルボン酸誘導体の効率的不斉合成

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase